This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Momentum Tell and the Yellen Timeline

By: Nicole Urken | 04/10/14 - 02:47 PM EDT

Stocks in this article: FEYENOWCELG

NEW YORK (TheStreet) - Talk about whiplash. Yesterday's surge upward was met today with, well, a selloff.

First off, much of this has been driven over confusion about the Fed, particularly in the vacuum between earnings seasons that we have experienced. First, on March 19th, Fed Chair Janet Yellen spooked the market via confusion, by suggesting that there would be a six month gap before rate increases after quantitative easing ends. Now, Yellen made an effort to clarify her remarks at a Chicago speech on March 31st, but ultimately many still questioned just what the Federal Reserve's strategy would be.  Now, yesterday, the market rose significantly on the Fed Minutes from that fateful March meeting. Now we know that the Fed actually met ahead (on March 4) of their last policy meeting to debate how and if to alter the guidance on short-term interest rates and that the agenda did not contemplate any policy decisions.

In response, we got a surge in many of the momentum names that had been pummeled, including names like FireEye (FEYE - Get Report), ServiceNow (NOW - Get Report), and Celgene (CELG - Get Report). We saw outperformance in healthcare--led by a bounceback in biotechs-- along with industrials and materials. Even financials were up as part of the cyclical rally, despite the higher certainty of lower rates. Why? More hope for loan growth and fee-based businesses.

Today? Another sell off, hitting the key momentum names. The underperformers of yesterday, the utilities, are leading the market today. Pressure today continued from liquidation at hedge funds, not to mention continued global uncertainty and higher appetite for high quality companies with strong dividends.

Ultimately, the momentum names have been key to following the market--whether they be the speculative biotech names, the cloud-based technology names, or the social cohort.

So what to do? Are these opportunities, or is buying now equivalent to catching a falling knife?

Answer: The fundamentals of many of these companies are unchanged. Even the large cap biotechs like Biogen (BIIB) that have some case-specific issues surrounding pricing ultimately have not seen their stories changed. But we will be in a house of pain until we start getting some positive earnings numbers with strong outlooks. It all comes down to earnings season which is just kicking off ... to see if we can turn around this onslaught of selling.

PS: Remember, the market as a whole-- despite much volatility--has done quite well. A "much ado about nothing" market.

--Written by Nicole Urken in New York.

>Contact by Email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs